Lifestream and Polymer resolve patent wrangle:
This article was originally published in Clinica
Executive Summary
Lifestream Technologies has reached a settlement in its patent infringement lawsuit filed against Polymer Technology Systems, a private developer of rapid cholesterol tests. In the agreement, Polymer is to make royalty payments to Lifestream for future sales of products incorporating the latter's HDL (high density lipoprotein) technology, the subject of the dispute. The resolution follows shortly after Lifestream won its appeal to have overturned an initial ruling that found Polymer not guilty of infringement.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.